You’re reciting Patent Law 101 and stopping right before the part that actually matters.
Yes — all patents cite prior art. That’s not a weakness, it’s a requirement. What determines value isn’t whether prior art exists, but whether the claims introduce non-obvious, enabling improvements that are distinctly claimable. Courts invalidate patents for obviousness, not for “being improvements.”
An expired foundational patent does not place the field into a free-for-all. It opens the door for new, narrower, defensible claims — especially around formulation control, delivery mechanics, containment, manufacturing processes, and clinical use cases. That’s exactly how modern medical-device portfolios are built.
Calling later patents “weak” without addressing:
• claim scope
• claim novelty
• prosecution history
• examiner allowances
isn’t analysis — it’s assertion.
Also, “status expired – lifetime” applies only to that specific patent, not to later-issued patents that stand on their own priority dates. Anyone suggesting otherwise fundamentally misunderstands how patent families work.
If “anyone could just do it better,” they would — and they’d still have to design around active claims. That’s how competitive IP landscapes actually function.
Bottom line:
Expired doesn’t mean irrelevant
Improvement doesn’t mean obvious
Prior art doest’t mean invalid
That argument sounds convincing on message boards — it doesn’t survive contact with patent examiners, courts, or real competitors.
Market Data 
Markets 
AI
